Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

NCT00820924 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Breast

Interventions

DRUG: LAPATINIB

Sponsor

GlaxoSmithKline